BioDIP Publications
Diabetologia 2014 Mar 20;57(3):522-31
Mesenchymal stromal cells improve transplanted islet survival and islet function in a syngeneic mouse model.
Islet transplantation is used therapeutically in a minority of patients with type 1 diabetes. Successful outcomes are hampered by early islet beta cell loss. The adjuvant co-transplantation of mesenchymal stromal cells (MSCs) has the promise to improve islet transplant outcome.
Authors
Borg DJ, Weigelt M, Wilhelm C, Gerlach M, Bickle M, Speier S, Bonifacio E, Hommel A
Year
2014
PubMed ID
24253203